PubMed HealthSearch

PubMed · 7971847

[Tuberculosis: a new priority].

Abstract

Tuberculosis is one of the most widespread diseases affecting more than 8 million subjects. The death toll has been estimated at 3 million persons annually. In France, the incidence in 1991 was 15 per 100,000 inhabitants with wide regional variation (37 per 100,000 in Paris and surrounding areas). It is difficult to interpret variations in incidence which would appear to be on the rise since 1993. (The increase may be a real rise in incidence or simply due to better registration as a result of reports of HIV infection.) In industrialized countries, economic factors, movements in populations, restrictive policies in antituberculosis health care and HIV infection are all factors leading to an increased incidence in tuberculosis. These observations strongly suggest the need for reorganizing our health care policy in the fight against tuberculosis, improving modern techniques in bacteriological identification and imagining new modalities of prevention and treatment. Special emphasis must be placed on research still required before this curable disease can be eradicated.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

M Molimard, A Hirsch, J Chrétien. [Tuberculosis: a new priority].. https://pubmed.ncbi.nlm.nih.gov/7971847/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus.

BACKGROUND: Interleukin-2 is a cytokine that regulates the proliferation and differentiation of lymphocytes. In preliminary studies, intermittent infusions of interleukin-2 led to increases in CD4 counts in patients with human immunodeficiency virus (HIV) infection and more than 200 CD4 cells per cubic millimeter. We conducted a controlled study to evaluate the long-term effects of such therapy on both CD4 counts and the viral burden. METHODS: Sixty HIV-infected patients with base-line CD4 counts above 200 cells per cubic millimeter were randomly assigned to receive either interleukin-2 plus antiretroviral therapy (31 patients, 1 of whom was lost to follow-up) or antiretroviral therapy alone (29 patients). Interleukin-2 was administered every two months for six cycles of five days each, starting at a dosage of 18 million i.u. per day. Safety and immunologic and virologic measures were monitored monthly until four months after the last treatment cycle. RESULTS: In patients treated with interleukin-2, the mean (+/-SE) CD4 count increased from 428 +/- 25 cells per cubic millimeter at base line to 916 +/- 128 at month 12, whereas in the control group, the mean CD4 count decreased from 406 +/- 29 cells per cubic millimeter to 349 +/- 41 (P < 0.001). There were no significant differences between the groups in serial measurements of the plasma HIV RNA or p24 antigen concentration during the 12 months of treatment. Constitutional symptoms (fever, malaise, and fatigue) and asymptomatic hyperbilirubinemia were the chief dose-limiting toxic effects of interleukin-2 therapy. CONCLUSIONS: In patients with HIV infection and base-line CD4 counts above 200 cells per cubic millimeter, intermittent infusions of interleukin-2 produced substantial and sustained increases in CD4 counts with no associated increase in plasma HIV RNA levels.

AIDS-Related Opportunistic Infections